Petition to HHS: Expand Access to GLP-1s Through 28 U.S.C. § 1498
Public Citizen filed a petition requesting that the United States Department of Health and Human Services authorize generic competition for Novo Nordisk’s semaglutide (marketed as Ozempic, Wegovy, and Rybelsus) and Eli Lilly’s tirzepatide (marketed as Mounjaro and Zepbound), overcoming the drugmakers’ patent barriers to improve access to expensive GLP-1 medications for weight loss, type 2 diabetes, and other conditions.
Read the full petition here.
Read a summary of key points here.